| Cohort 1 (n = 59) | Cohort 2 (n = 185) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DFS | Univariate | Multivariate | Univariate | Multivariate | |||||||||
| Variable | Item | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value |
| Age | < 50 years | 1 | 1 | ||||||||||
| > 50 years | 1.642 | (0.782–3.448) | 0.191 | 2.053 | (0.962–4.381) | 0.063 | 1.555 | (1.024–2.360) | 0.038 | 1.845 | (1.203–2.829) | 0.005 | |
| Sex | Male | 1 | 1 | ||||||||||
| Female | 1.276 | (0.615–2.646) | 0.513 | – | – | – | 0.853 | (0.570–1.279) | 0.442 | – | – | – | |
| WBC | < 20 × 109/L | 1 | 1 | ||||||||||
| < 20 × 109/L | 0.695 | (0.332–1.455) | 0.335 | – | – | – | 1.041 | (0.694–1.561) | 0.846 | – | – | – | |
| FLT3 | FLT3/ITD– | 1 | 1 | ||||||||||
| FLT3/ITD+ | 0.914 | (0.424–1.971) | 0.818 | – | – | – | 1.636 | (1.063–2.519) | 0.025 | 1.606 | (0.998–2.584) | 0.051 | |
| NPM1 | NPM1– | 1 | 1 | ||||||||||
| NPM1+ | 1.369 | (0.596–3.143) | 0.459 | – | – | – | 0.793 | (0.528–1.193) | 0.266 | – | – | – | |
| FLT3/NPM1 | Favorable | 1 | 1 | ||||||||||
| Unfavorable | 1.247 | (0.490–3.176) | 0.643 | – | – | – | 2.229 | (1.345–3.693) | 0.002 | 2.079 | (1.203–3.595) | 0.009 | |
| NEDD9 | Underexpression | 1 | 1 | ||||||||||
| Overexpression | 0.372 | (0.129–1.072) | 0.067 | 0.304 | (0.103–0.893) | 0.030 | 0.468 | (0.273–0.803) | 0.006 | 0.426 | (0.241–0.753) | 0.003 | |
| BCAR1 | Underexpression | 1 | 1 | ||||||||||
| Overexpression | 0.782 | (0.290–2.111) | 0.628 | – | – | – | 0.947 | (0.573–1.562) | 0.830 | – | – | – | |
COX test was used to analyze the statistical significance in OS and DFS. P value < 0.05 was considered statistically significant (Bold values). “-“ indicates that variables were not included in the multivariate analyses (P value > 0.250 in the univariate analysis). HR; Hazard ratio. CI; Confidence interval. OS; Overall survival. DFS, Disease-free survival. WBC; White blood cells.